Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the authors observed that treatment patterns for new benign prostatic hyperplasia largely aligned with guidelines, but 5-α reductase inhibitors were used inappropriately based on prostate size as indicated by prostate specific antigen.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This study found that lower urinary tract symptoms in older men with benign prostatic hyperplasia negatively impact sexual function and mental health, suggesting the importance of early intervention to improve quality of life.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.

In laboratory tests, this study found that a novel natural composition targeting 5-alpha reductase and inflammatory pathways reduced disease-related markers in androgenetic alopecia and benign prostatic hyperplasia more effectively than finasteride.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

This study found that finasteride was nongenotoxic in Drosophila, while doxazosin mesylate and saw palmetto induced homologous recombination, indicating potential genotoxic actions under the test conditions.

This study found that finasteride and its combination with terazosin significantly reduced PSA levels in patients with benign prostatic hyperplasia, whereas terazosin alone showed no clinically significant effect.

In a rat model of benign prostatic hyperplasia, this study found that purple corn extract may improve symptoms by inhibiting prostate enlargement, reducing androgen receptor signaling, and exerting anti-inflammatory effects.

This paper discusses the potential of targeting fibrosis in addressing lower urinary tract symptoms associated with benign prostatic hyperplasia, but it provides no new clinical findings and highlights the need for further research.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study identified Aquilaria sinensis and Piper cubeba as tropical plants with potential anti-androgenic and anti-estrogenic properties that could help prevent or alleviate benign prostatic hyperplasia and prostate cancer.

This case report suggests a potential link between the intake of Serenoa repens, commonly known as Saw palmetto, and the onset of erectile dysfunction.

This article discusses the inaugural andrology issue of Reviews in Endocrine & Metabolic Disorders, reporting no new clinical findings but showcasing review articles on andrology by international experts.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This clinical trial in Poland found that using finasteride, alone or with an alpha-blocker, reduced prostate adenoma size by 40% and improved micturition in patients with benign prostatic hyperplasia.

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

This study is designed to explore the pathogenesis of BPH and assess the effectiveness of combining finasteride and anastrozole as a treatment in rats, with a focus on genetic polymorphisms and hormone regulation.

This study reports that although saw palmetto extract is marketed as a natural alternative for hair loss and prostate health, its unregulated status may pose safety and efficacy risks to consumers.

In this study, researchers observed that Cuscuta reflexa extract mitigated inflammation and oxidative stress in testosterone-induced benign prostatic hypertrophy in Wistar rats, suggesting its potential as an adjunctive therapy for BPH.

This review analyzed current research on finasteride and dutasteride and found insufficient evidence to fully elucidate their role in metabolic adverse events, such as liver disease and diabetes, due to a lack of detailed pathophysiologic understanding; further studies are needed to clarify these mechanisms.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

This study suggests that identified polymorphisms may serve as markers for assessing an individual's risk of developing prostate cancer.

Long-term use of finasteride may cause breast cancer in men.

This study reported two cases of finasteride-induced melasma, suggesting clinicians should consider 5-ARI exposure in patients with new-onset or persistent facial hyperpigmentation, especially in those with darker skin types.

In this study, researchers synthesized silver nanoparticles using an extract from Mitracarpus scaber and found them to have significant hepatoprotective and anti-hyperplastic effects in rats, suggesting potential for treating liver injury and benign prostatic hyperplasia.